ARL11

Across TCGA pan-cancer cohorts, ARL11 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARL11 data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher ARL11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL11 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

LGG, SARC, and COAD are the cancer types where ARL11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.185	0.832	<.001	12	view →
SARC	DFS	Median	All	0.101	0.632	.011	12	view →
COAD	OS	Median	All	1.000	0.592	.020	10	view →
ACC	DFS	Median	IV	0.010	0.383	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	All	0.258	0.787	.018	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARL11–LGG (DFS)

Open the LGG breakdown →